Segment and Geographical Information

3 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Segment and Geographical Information

14. Segment and Geographical Information

The Company’s management evaluates performance and allocates resources based on reported results for two reportable segments, based on the criteria set forth in FASB ASC Topic 280, Segment Reporting, as follows: (1) the Medical Device unit, which is comprised of manufacturing balloons and catheters used for a variety of interventional cardiology, peripheral and other applications, surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device, with end markets that include coronary, peripheral, and neurovascular, and urology, among others, and (2) the In Vitro Diagnostics unit, which consists of component products and technologies for diagnostic immunoassay as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, antigens and surface coatings.  

During fiscal 2016, the Company acquired Creagh Medical and NorMedix, which are included in the Medical Device segment subsequent to the respective acquisition dates, as further discussed in Note 3.

The tables below present segment revenue, operating income and depreciation and amortization, as follows:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016			2015
Revenue:
Medical Device	$	13,757		$	12,247
In Vitro Diagnostics		4,004			4,294
Total revenue	$	17,761		$	16,541
Operating income:
Medical Device	$	3,719		$	3,830
In Vitro Diagnostics		1,456			1,643
Total segment operating income		5,175			5,473
Corporate		(1,907	)		(1,534	)
Total operating income	$	3,268		$	3,939
Depreciation and amortization:
Medical Device	$	1,004		$	487
In Vitro Diagnostics		103			222
Corporate		175			200
Total depreciation and amortization	$	1,282		$	909

The Corporate category includes expenses that are not fully allocated to Medical Device and In Vitro Diagnostics segments.  These Corporate costs are related to functions, such as executive management, corporate accounting, legal, human resources and Board of Directors. Corporate may also include expenses, such as litigation, which are not specific to a segment and thus not allocated to the operating segments.

Asset information by operating segment is not presented because the Company does not provide its chief operating decision maker assets by operating segment, as the data is not readily available or significant to the decision making process.